OrganOx is at the forefront of changing the way donor organs are preserved in the critical time between donation and transplantation. OrganOx accessed venture capital via the Enterprise Capital Funds (ECF) programme, which it used to fund the clinical studies to secure market approval for its product, a complex class III medical device.